Русский
Clinical and metabolic peculiarities in male patients with type 2 diabetes mellitus and hypogonadism
DOI: https://dx.doi.org/10.18565/therapy.2023.9.7-15
Skuridina D.V., Demidova T.Yu.
N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia, Moscow
The aim: to study the clinical and metabolic peculiarities of type 2 diabetes in male patients with testosterone deficiency. Target functions: to identify the prevalence of testosterone deficiency in different age groups in male patients with T2 DM; to estimate the incidence of hypogonadism, including also among men having diabetes mellitus for about ≤1 year; to compare anthropometric characteristics of male patients with T2 DM and hypogonadism and without it; to compare carbohydrate metabolism rates in both groups; to estimate cardiovascular risk (CVR) factors – the frequency of arterial hypertension (AH) and lipid profile indexes.
Material and methods. The first stage included laboratory diagnosis of hypogonadism in the general population of male patients with T2 DM (n=287). The second stage of the study included only patients with less than 1 year of diabetes mellitus 2, subject to compensation of carbohydrate metabolism – a totally 36 persons (19 with diagnosed hypogonadism and 17 without hypogonadism). Serum analysis for total testosterone was performed from 07.00 to 11.00 am. At all stages of the study, BMI, waist circumference (WC), hip circumference (HC), WC/HR were estimated, bioimpedance analysis of body composition and blood pressure measurements were also performed. Laboratory parameters included HbA1c, fasting plasma glucose, and lipid profile.
Results. The incidence of hypogonadism was 46,8% in the general sample of patients (42,8% among men <55 years old and 51,1% among men ≥55 years old) and 52,8% in the second stage of the study among men with ≤1 year of DM duration. Patients with hypogonadism had a higher % of fat mass and a tendency to higher Waist/Hips measurement index. AH in male patients with hypogonadism took place more common, and the lipid profile had more atherogenic characteristics.
Conclusion. Among male patients with T2 DM, even with compensation of carbohydrate metabolism, hypogonadism occurs in almost every second case, regardless of age. Male patients with T2 DM and androgen deficiency have potentially higher CVR due to severe atherogenic dyslipidemia and more often developing AH. Moreover, male patients with androgen deficiency and T2 DM lasting ≤1 year, even with carbohydrate metabolism compensation, also have a higher % of fat mass and CVR, which dictates the need for an independent assessment of testosterone levels in newly diagnosed T2 DM, especially in patients with visceral obesity.
Literature
1. Dhindsa S., Prabhakar S., Sethi M. et al. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab. 2004; 89(11): 5462–68. https://dx.doi.org/10.1210/jc.2004-0804. 2. Дедов И.И., Шестакова М.В., Майоров А.Ю. с соавт. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 11-й выпуск. Сахарный диабет. 2023; 26(S2): 1–231. [Dedov I.I., Shestakova M.V., Mayorov A.Yu. et al. Standards of specialized diabetes care. 11th edition. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. Sakharnyy diabet = Diabetes Mellitus. 2023; 26(S2): 1–231 (In Russ.)]. https://dx.doi.org/10.14341/DM13042. 3. Bhasin S., Cunningham G.R., Hayes F.J. et al.; Task Force, Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010; 95(6): 2536–59.https://dx.doi.org/10.1210/jc.2009-2354. 4. Дедов И.И., Шестакова М.В., Майоров А.Ю. с соавт. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 9-й выпуск. Сахарный диабет. 2019; 22(S1–1): 1–144. [Dedov I.I., Shestakova M.V., Mayorov A.Yu. et al. Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 9th edition. Sakharnyy diabet = Diabetes Mellitus. 2019; 22(S1–1): 1–144 (In Russ.)].https://dx.doi.org/10.14341/DM221S1. EDN: LDOTJF. 5. Дедов И.И., Мельниченко Г.А., Шестакова М.В. с соавт. Рекомендации по диагностике и лечению дефицита тестостерона (гипогонадизма) у мужчин с сахарным диабетом. Ожирение и метаболизм. 2017; 14(4): 83–92. [Dedov I.I. Melnichenko G.A., Shestakova M.V. et al. Recommendations for the diagnosis and treatment of testosterone deficiency (hypogonadism) in men with diabetes mellitus. Ozhirenie i metabolizm = Obesity and Metabolism. 2017; 14(4): 83–92 (In Russ.)].https://dx.doi.org/10.14341/omet2017483-92. EDN: QHJFBB. 6. Дедов И.И., Мокрышева Н.Г., Мельниченко Г.А. с соавт. Проект клинических рекомендаций «Синдром гипогонадизма у мужчин». Ожирение и метаболизм. 2021; 18(4): 496–507. [Dedov I.I., Mokrysheva N.G., Melnichenko G.A. et al. Draft clinical guidelines «Hypogonadism syndrome in men». Ozhirenie i metabolizm = Obesity and Metabolism. 2021; 18(4): 496–507 (In Russ.)].https://dx.doi.org/10.14341/omet12817. EDN: FUWRTV. 7. Grossmann M., Matsumoto A.M. A perspective on middle-aged and older men with functional hypogonadism: Focus on holistic management. J Clin Endocrinol Metab. 2017; 102(3): 1067–75. https://dx.doi.org/10.1210/jc.2016-3580. 8. Ding E.L., Song Y., Malik V.S., Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: A systematic review and meta-analysis. JAMA. 2006; 295(11): 1288–99. https://dx.doi.org/10.1001/jama.295.11.1288. 9. Malipatil N.S., Yadegarfar G,. Lunt M. et al. Male hypogonadism: 14-year prospective outcome in 550 men with type 2 diabetes. Endocrinol Diabetes Metab. 2019; 2(3): e00064. https://dx.doi.org/10.1002/edm2.64. 10. Free & Bioavailable Testosterone calculator. URL: https://www.issam.ch/freetesto.htm (date of access – 01.11.2023).
About the Autors
Daria V. Skuridina, assistant at the Department of endocrinology of the Faculty of general medicine, N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia. Address: 117321, Moscow,
1 Ostrovityanova St.
E-mail: shurpesha@mail.ru
ORCID: https://orcid.org/0000-0002-6899-4457
Tatyana Yu. Demidova, MD, professor, head of the Department of endocrinology of the Faculty of general medicine, N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia. Address: 117321, Moscow, 1 Ostrovityanova St.
E-mail: t.y.demidova@gmail.com
ORCID: https://orcid.org/0000-0001-6385-540X
Similar Articles
